One thing that The NaDDir* didn’t address on last week’s bizarre conference call by everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), was the recruiting status of the much vaunted “CD12” study of loserlimab in severe-to-critical Covid-19 patients.
Recall that prestigious Ivy League university in Connecticut that was participating in the study (but never actually recruited a single patient?). Sure you do. Here’s the Clinicaltrials.gov record of study locations as of mid-August:
On August 31st, the company quietly deleted Yale from the trial location list (and it looks like Eisenhower Health in California dumped CYDY too).
And speaking of trial sites, remember that press release back on August 20th, where Cytodyn claimed that they received authorization to enroll UK patients, commencing immediately, into its ongoing Covid-19 trial?
Go back and review the list of trial sites as of August 31st, available here. Interesting that there are no UK sites listed. Not one. On the conference call last week, The NaDDir* did make some curious comments about UK trial enrollment:
“We received great news today. UK ethical committee approved CD12 study to be conducted in the UK. Now, the study can officially be initiated. Please also see our MHRA comments below”. They have recommended, CytoDyn to resubmit the CytoDyn CD12 COVID-19 study to the urgent public health, UPH scheme.”
Was the company lying about being approved to begin recruiting UK patients in the August 20th press release? It seems so. And exactly why did the company need to resubmit the study? Was it really because wink wink nudge nudge the UK health authorities love it so much? Or is it (much more likely given Cytodyn’s history), because the original filing was deficient in some way? Or maybe the MHRA (like the FDA with Cytodyn’s pathetic HIV BLA) just wanted a Double Dose of The NaDDir’s* sweet sweet regulatory filings?
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.
